Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck (NYSE:MRK) announced Saturday that its anti-PD-1 therapy Keytruda (pembrolizumab) as part of a combination regimen ...